Table 1 Baseline characteristics and intergroup differences at the time of allocation (per protocol set).

From: Post hoc analysis of a randomized placebo-controlled trial suggests potential visual benefits of branched-chain amino acids in retinitis pigmentosa

Characteristics

TK-98 (44 patients, 87 eyes)

Placebo (25 patients, 46 eyes)

Intergroup difference

Intergroup comparison P Value

Annual change in the placebo group31

Age, year

51.0 ± 11.3

52.1 ± 14.4

− 1.1

0.628

 

Sex, n, female/male, (female %)

23/21 (52.3%)

14/11 (56.0%)

 

0.462

 

MD value at the time of allocation (10-2) (dB)

− 14.8 ± 4.9

− 14.2 ± 5.1

− 0.6#

0.549

− 0.52

MD slope just before the allocation (dB/year)*

− 0.11 ± 0.92

− 0.42 ± 0.89

0.31

0.071

 

Total point score (10-2) (dB)

1229.2 ± 329.6

1257.1 ± 361.3

− 27.9

0.659

− 35.4

Total point score (30-2) (dB)

482.4 ± 350.7

469.5 ± 309.1

12.9

0.838

− 21.9

Ellipsoid zone length (µm)

1557.4 ± 1362.3

2045.5 ± 1287.8

− 488.1#

0.051

− 95.6

Time from onset of first subjective symptoms (year)

28.5 ± 13.1

26.9 ± 12.9

1.6

0.510

 

Lens, n, Phakia/Pseudophakia, (Phakia %)

75/12 (86.2%)

29/17 (63.0%)

− 1.1

0.002

 
  1. Characteristics are shown as mean ± standard deviation.
  2. *Mean deviation (MD) slope just before allocation was calculated using linear regression with MD values on the Humphrey visual-field test 10-2 observed up to 3 years prior to inclusion in the clinical trial, including the result at the time of allocation.
  3. #Variables for which the absolute difference in mean values between the two groups exceeded the absolute annual change in the placebo group.
  4. Total point score was calculated as the sum of visual sensitivities for all measured locations. dB decibel.
Back to article page